However, as EVG is co-administered with other antiretroviral drugs and pharmacoenhancer such as COBI or RTV, it is expected that these combination therapies may alter the inhibitory effects of EVG on the CYP3A4 enzyme [1 ] at least during the acute phase of drug exposure.
Source: wiktionary